AMENDMENT TO MASTER RESEARCH AND COLLABORATION AGREEMENTMaster Research and Collaboration Agreement • April 30th, 2020 • Agios Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Master Research and Collaboration Agreement (this “Amendment”) is entered into as of February 5, 2020 (the “Amendment Date”), by and among Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”), on the one hand, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under the Master Collaboration Agreement (as defined below) in the United States, and Celgene RIVOT Ltd., a Bermuda entity (“Celgene RIVOT”), with respect to all rights and obligations under the Master Collaboration Agreement outside of the United States (Celgene RIVOT and Celgene Corp. together, “Celgene”), on the other hand. Capitalized terms used herein and not defined herein shall have the meanings ascribed to them in the Master Collaboration Agreement.
AMENDMENT II TO LICENSE AGREEMENTLicense Agreement • April 30th, 2020 • Agios Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Amendment II to License Agreement (this “Amendment”), dated as of March 2, 2020 (the “Amendment Effective Date”), is made and entered into by and between Agios Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with a principal place of business at 88 Sidney Street, Cambridge, MA 02139 (“Agios”) and CStone Pharmaceuticals, a corporation organized and existing under the laws of the Cayman Islands, with a registered address at P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands (“Licensee”). Each of Agios and Licensee may be referred to herein as a “Party” and Agios and Licensee may be referred to herein collectively as the “Parties.”
AMENDMENT I TO LICENSE AGREEMENTLicense Agreement • April 30th, 2020 • Agios Pharmaceuticals, Inc. • Pharmaceutical preparations
Amendment I to License Agreement (this “Amendment”), dated as of February 6, 2020 (the “Amendment Effective Date”), by and between Agios Pharmaceuticals, Inc. (“Agios”) and CStone Pharmaceuticals (“Licensee”). Each of Agios and Licensee may be referred to herein as a “Party” and Agios and Licensee may be referred to herein collectively as the “Parties.”
